TAILIEUCHUNG - Báo cáo hóa học: "TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status | Herreros-Villanueva et al. Journal of Translational Medicine 2010 8 15 http content 8 1 15 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status Marta Herreros-Villanueva1 Pilar Muniz2 Carlos García-Girón3 Mónica Cavia-Saiz1 María J Coma del Corral1 Abstract Background Although there have been many studies on the p73 gene some of its functions still remain unclear. There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain drugs such as oxaliplatin and cetuximab which are drugs currently used in colorectal cancer. The purpose of this study was to evaluate the impact ofTAp73 expression on oxaliplatin and cetuximab-based chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status. Methods TAp73 was analyzed in three colorectal tumor cell lines HT-29 SW-480 and Caco-2. mRNA TAp73 was determined using Real time PCR TAp73 protein by immunoblotting and cell viability was analyzed by the MTT method. Results We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin in monotherapy or combined with cetuximab when B-Raf is mutated. This was statistically significant and was also associated with higher cell viability after the treatment. Conclusions Here for the first time we report that there is a signaling loop between B-Raf activation and p73 function. Low expression ofTAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab. Background The incidence of colorectal cancer has been increasing in the last few years while the age of diagnosis is decreasing and today it is the third or fourth cause of death in the world. The treatment of metastatic colorectal cancer mCRC has changed drastically since the .

TÀI LIỆU LIÊN QUAN
TAILIEUCHUNG - Chia sẻ tài liệu không giới hạn
Địa chỉ : 444 Hoang Hoa Tham, Hanoi, Viet Nam
Website : tailieuchung.com
Email : tailieuchung20@gmail.com
Tailieuchung.com là thư viện tài liệu trực tuyến, nơi chia sẽ trao đổi hàng triệu tài liệu như luận văn đồ án, sách, giáo trình, đề thi.
Chúng tôi không chịu trách nhiệm liên quan đến các vấn đề bản quyền nội dung tài liệu được thành viên tự nguyện đăng tải lên, nếu phát hiện thấy tài liệu xấu hoặc tài liệu có bản quyền xin hãy email cho chúng tôi.
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.